Skip to content
Screener

Palvella Therapeutics PVLA Royalty Agreement Liability

Royalty Agreement Liability at other companies

PTH
Pelthos TherapeuticsPTHS
$5M+300%
ESP
ESPRESPR
$72.6M+1.0%
PTH
Pelthos TherapeuticsPTHS
13%
uniQure logo
uniQureQURE
$489.33M+7.5%
PTH
Pelthos TherapeuticsPTHS
30%+22.5pp
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$300M0.0%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%
Enterprise value$2.03B

Profitability

See full
Operating margin-183.2%
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept pvla:RoyaltyAgreementLiability.

The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210463
Line itemMarch 31, 2026December 31, 2025
Accrued expenses and other current liabilities3,4634,351
Total current liabilities9,11511,344
Long-term portion of operating lease liability375431
Royalty agreement liability19,79917,760
Derivative liabilities – royalty agreement2,1572,041
Total liabilities31,44631,576
Commitments and contingencies (Note 8)
Stockholders’ equity:

Item 1. Financial Statements.

FAQ

What is Palvella Therapeutics's royalty agreement liability?
Palvella Therapeutics (PVLA) reported royalty agreement liability of $19.8M in Q1 2026.
How has Palvella Therapeutics's royalty agreement liability changed year-over-year?
Palvella Therapeutics's royalty agreement liability increased by 50.5% year-over-year, from $13.16M to $19.8M.
What is the long-term trend for Palvella Therapeutics's royalty agreement liability?
Over 2 years (2023 to 2025), Palvella Therapeutics's royalty agreement liability has grown at a 48.5% compound annual growth rate (CAGR), from $8.05M to $17.76M.
What does royalty agreement liability mean?
This represents the present value of future payment obligations owed to third parties based on licensing agreements or intellectual property rights associated with the company's product pipeline. It reflects the long-term financial burden of external technology acquisition or development partnerships. Investors use this to assess the impact of future revenue sharing on the company's long-term profitability and capital structure.

Ask your AI about Palvella Therapeutics's royalty agreement liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude